300702 天宇股份
已收盘 04-21 15:00:00
资讯
新帖
简况
天宇股份：公司目前暂无仲丁基锂连续流技术的应用
证券之星 · 11:33
天宇股份：公司目前暂无仲丁基锂连续流技术的应用
天宇股份（300702）披露收购上海星可高纯溶剂有限公司部分股权暨关联交易议案获通过，4月15日股价下跌0.3%
证券之星 · 04-15
天宇股份（300702）披露收购上海星可高纯溶剂有限公司部分股权暨关联交易议案获通过，4月15日股价下跌0.3%
天宇股份最新公告：拟3.34亿元收购上海星可87.82%股权
证券之星 · 03-30
天宇股份最新公告：拟3.34亿元收购上海星可87.82%股权
3月27日天宇股份涨6.05%，湘财医药健康混合A基金重仓该股
证券之星 · 03-27
3月27日天宇股份涨6.05%，湘财医药健康混合A基金重仓该股
天宇股份（300702）披露关于变更财务总监及聘任证券事务代表的公告，2月24日股价下跌2.57%
证券之星 · 02-24
天宇股份（300702）披露关于变更财务总监及聘任证券事务代表的公告，2月24日股价下跌2.57%
天宇股份最新公告：全资子公司药品卡格列净片获得药品注册证书
证券之星 · 02-06
天宇股份最新公告：全资子公司药品卡格列净片获得药品注册证书
2月6日天宇股份涨5.35%，湘财医药健康混合A基金重仓该股
证券之星 · 02-06
2月6日天宇股份涨5.35%，湘财医药健康混合A基金重仓该股
天宇股份：关于您提出的股份回购等建议，公司董事会及管理层会结合资金状况与发展规划认真研究评估
证券之星 · 02-05
天宇股份：关于您提出的股份回购等建议，公司董事会及管理层会结合资金状况与发展规划认真研究评估
天宇股份：公司生产经营一切正常
证券之星 · 02-04
天宇股份：公司生产经营一切正常
股市必读：天宇股份（300702）2月2日收盘跌10.08%，主力净流出94.98万元
证券之星 · 02-03
股市必读：天宇股份（300702）2月2日收盘跌10.08%，主力净流出94.98万元
2月2日天宇股份跌10.08%，湘财医药健康混合A基金重仓该股
证券之星 · 02-02
2月2日天宇股份跌10.08%，湘财医药健康混合A基金重仓该股
天宇股份（300702）披露2025年度业绩预告，1月30日股价下跌0.38%
证券之星 · 01-30
天宇股份（300702）披露2025年度业绩预告，1月30日股价下跌0.38%
天宇股份（300702）披露2026年度日常关联交易预计公告，1月26日股价上涨1.28%
证券之星 · 01-26
天宇股份（300702）披露2026年度日常关联交易预计公告，1月26日股价上涨1.28%
天宇股份（300702）披露全资子公司药品获得批准，1月22日股价下跌1.36%
证券之星 · 01-22
天宇股份（300702）披露全资子公司药品获得批准，1月22日股价下跌1.36%
天宇股份（300702）披露全资子公司首次通过高新技术企业认定，1月19日股价上涨1.03%
证券之星 · 01-19
天宇股份（300702）披露全资子公司首次通过高新技术企业认定，1月19日股价上涨1.03%
天宇股份(300702.SZ)：阿帕他胺原料药通过CDE审评
智通财经 · 01-07
天宇股份(300702.SZ)：阿帕他胺原料药通过CDE审评
天宇股份（300702）披露变更签字注册会计师公告，1月6日股价下跌0.41%
证券之星 · 01-06
天宇股份（300702）披露变更签字注册会计师公告，1月6日股价下跌0.41%
天宇股份（300702）披露完成《公司章程》备案，12月23日股价上涨0.76%
证券之星 · 2025-12-23
天宇股份（300702）披露完成《公司章程》备案，12月23日股价上涨0.76%
天宇股份（300702）披露全资子公司药品获得批准，12月22日股价下跌1.54%
证券之星 · 2025-12-22
天宇股份（300702）披露全资子公司药品获得批准，12月22日股价下跌1.54%
天宇股份最新公告：全资子公司药品盐酸曲唑酮片获得批准
证券之星 · 2025-12-22
天宇股份最新公告：全资子公司药品盐酸曲唑酮片获得批准
加载更多
公司概况
公司名称：
浙江天宇药业股份有限公司
所属行业：
医药制造业
上市日期：
2017-09-19
主营业务：
浙江天宇药业股份有限公司的主营业务是中间体、原料药以及制剂业务的研发、生产与销售。公司的主要产品是降血压类原料药及中间体、降血糖类原料药及中间体、抗凝血类原料药及中间体、制剂类、抗哮喘类原料药及中间体、降血脂类原料药及中间体。
发行价格：
22.41
{"stockData":{"symbol":"300702","market":"SZ","secType":"STK","nameCN":"天宇股份","latestPrice":22.19,"timestamp":1776755004000,"preClose":22.28,"halted":0,"volume":2042574,"delay":0,"changeRate":-0.004,"floatShares":211000000,"shares":348000000,"eps":0.5511,"marketStatus":"已收盘","change":-0.09,"latestTime":"04-21 15:00:00","open":22.4,"high":22.4,"low":21.99,"amount":45222100,"amplitude":0.0184,"askPrice":22.2,"askSize":31,"bidPrice":22.19,"bidSize":57,"shortable":0,"etf":0,"ttmEps":0.5511,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776821400000},"marketStatusCode":5,"adr":0,"adjPreClose":22.28,"symbolType":"stock","openAndCloseTimeList":[[1776735000000,1776742200000],[1776747600000,1776754800000]],"highLimit":24.51,"lowLimit":20.05,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":347977159,"isCdr":false,"pbRate":2.08,"roa":"--","peRate":40.264925,"roe":"6.12%","epsLYR":0.16,"committee":-0.615385,"marketValue":7722000000,"turnoverRate":0.0097,"status":1,"floatMarketCap":4686000000},"requestUrl":"/m/hq/s/300702/news","defaultTab":"news","newsList":[{"id":"2629372709","title":"天宇股份：公司目前暂无仲丁基锂连续流技术的应用","url":"https://stock-news.laohu8.com/highlight/detail?id=2629372709","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629372709?lang=zh_cn&edition=full","pubTime":"2026-04-21 11:33","pubTimestamp":1776742423,"startTime":"0","endTime":"0","summary":"证券之星消息，天宇股份(300702)04月20日在投资者关系平台上答复投资者关心的问题。投资者提问：目前行业内在仲丁基锂连续流规模化生产上已出现明显技术领先企业，该技术直接决定高难度创新药分子的可开发性与商业化效率。请问公司是否掌握相关核心工艺？有无具体项目案例、产能规模及客户验证？若存在明显技术代差，将如何应对高端订单流失的风险？天宇股份回复：尊敬的投资者您好，公司目前暂无仲丁基锂连续流技术的应用。感谢您的关注以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100024580.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627335233","title":"天宇股份（300702）披露收购上海星可高纯溶剂有限公司部分股权暨关联交易议案获通过，4月15日股价下跌0.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627335233","media":"证券之星","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627335233?lang=zh_cn&edition=full","pubTime":"2026-04-15 22:25","pubTimestamp":1776263114,"startTime":"0","endTime":"0","summary":"截至2026年4月15日收盘，天宇股份报收于23.13元，较前一交易日下跌0.3%，最新总市值为80.49亿元。公告显示，浙江天宇药业股份有限公司于2026年4月15日召开2026年第一次临时股东会，会议由董事会召集，董事长屠勇军主持，采用现场与网络投票结合方式召开。出席会议股东共280名，代表股份占公司总股本的66.6622%。会议审议通过《关于收购上海星可高纯溶剂有限公司部分股权暨关联交易的议案》，关联股东林洁、屠勇军已回避表决。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500043210.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623259314","title":"天宇股份最新公告：拟3.34亿元收购上海星可87.82%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2623259314","media":"证券之星","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623259314?lang=zh_cn&edition=full","pubTime":"2026-03-30 19:31","pubTimestamp":1774870280,"startTime":"0","endTime":"0","summary":"天宇股份(300702.SZ)公告称，公司拟以支付现金方式收购上海星可高纯溶剂有限公司87.8173%股权，转让价格为3.34亿元。本次交易对方之一屠勇军为公司控股股东，构成关联交易。交易旨在优化产业链布局，减少关联交易。本次交易不构成重大资产重组，已获董事会审议通过，尚需提交股东会审议。标的公司主营业务为制备级、色谱级试剂的研发、生产与销售，以及有机溶剂废液资源化综合循环利用及处置业务，主要聚焦于生物医药、电子信息、科学研究等领域。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033000030225.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622849810","title":"3月27日天宇股份涨6.05%，湘财医药健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2622849810","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622849810?lang=zh_cn&edition=full","pubTime":"2026-03-27 16:17","pubTimestamp":1774599459,"startTime":"0","endTime":"0","summary":"证券之星消息，3月27日天宇股份涨6.05%，收盘报22.95元，换手率3.53%，成交量7.46万手，成交额1.7亿元。重仓天宇股份的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为湘财基金的湘财医药健康混合A。湘财医药健康混合A目前规模为0.16亿元，最新净值1.6505，较上一交易日上涨0.0%，近一年上涨37.15%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700033474.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613479168","title":"天宇股份（300702）披露关于变更财务总监及聘任证券事务代表的公告，2月24日股价下跌2.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613479168","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613479168?lang=zh_cn&edition=full","pubTime":"2026-02-24 17:33","pubTimestamp":1771925623,"startTime":"0","endTime":"0","summary":"截至2026年2月24日收盘，天宇股份报收于24.66元，较前一交易日下跌2.57%，最新总市值为85.81亿元。近日，天宇股份披露《关于变更财务总监及聘任证券事务代表的公告》。公告显示，公司于2026年2月13日召开第五届董事会第十九次会议，审议通过聘任王冲女士为公司财务总监，任期至第五届董事会届满；同时聘任陆梦瑶女士为公司证券事务代表，协助董事会秘书履行职责。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400033237.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609676155","title":"天宇股份最新公告：全资子公司药品卡格列净片获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2609676155","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609676155?lang=zh_cn&edition=full","pubTime":"2026-02-06 19:19","pubTimestamp":1770376784,"startTime":"0","endTime":"0","summary":"天宇股份公告称，公司全资子公司诺得药业近日收到国家药监局核准签发的卡格列净片的《药品注册证书》。该药品适应症为与二甲双胍联用改善成人2型糖尿病患者的血糖控制，不建议用于改善1型糖尿病患者的血糖控制。此外，诺得药业卡格列净片2024年10月获得国家药监局受理，截至2026年1月31日，公司及子公司对该品种的累计研发投入约1,320.70万元。该药品获得批件后可在境内生产、销售，有望增加公司制剂业务收入，提升市场竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600035350.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609563974","title":"2月6日天宇股份涨5.35%，湘财医药健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2609563974","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609563974?lang=zh_cn&edition=full","pubTime":"2026-02-06 16:34","pubTimestamp":1770366890,"startTime":"0","endTime":"0","summary":"证券之星消息，2月6日天宇股份涨5.35%，收盘报25.6元，换手率3.92%，成交量8.28万手，成交额2.11亿元。重仓天宇股份的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为湘财基金的湘财医药健康混合A。湘财医药健康混合A目前规模为0.16亿元，最新净值1.7685，较上一交易日上涨0.51%，近一年上涨54.59%。该公募基金现任基金经理为张泉。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600027067.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609701663","title":"天宇股份：关于您提出的股份回购等建议，公司董事会及管理层会结合资金状况与发展规划认真研究评估","url":"https://stock-news.laohu8.com/highlight/detail?id=2609701663","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609701663?lang=zh_cn&edition=full","pubTime":"2026-02-05 20:52","pubTimestamp":1770295952,"startTime":"0","endTime":"0","summary":"公司业绩实现翻倍增长，股价却大幅下跌，请问公司董事会及管理团队是否有考虑推出股份回购计划等提高市值的相关工作。感谢您的关注与建议。公司目前经营情况良好，我们会继续扎实做好主业以回报投资者。关于您提出的股份回购等建议，公司董事会及管理层会结合资金状况与发展规划认真研究评估，后续如有相关计划，我们将严格按照规定及时履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500037726.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608336581","title":"天宇股份：公司生产经营一切正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2608336581","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608336581?lang=zh_cn&edition=full","pubTime":"2026-02-04 11:34","pubTimestamp":1770176080,"startTime":"0","endTime":"0","summary":"证券之星消息，天宇股份02月03日在投资者关系平台上答复投资者关心的问题。投资者提问：公司1月30日发布业绩预告，预计2025年归母净利润同比增长114.53%，但股价却逆势下跌。二级市场股价波动受宏观经济、市场情绪等多重因素影响。目前公司生产经营一切正常，核心业务原料药、制剂业务稳步增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400016215.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608894431","title":"股市必读：天宇股份（300702）2月2日收盘跌10.08%，主力净流出94.98万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608894431","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608894431?lang=zh_cn&edition=full","pubTime":"2026-02-03 02:54","pubTimestamp":1770058450,"startTime":"0","endTime":"0","summary":"截至2026年2月2日收盘，天宇股份报收于23.38元，下跌10.08%，换手率5.31%，成交量11.21万手，成交额2.69亿元。当日关注点来自交易信息汇总：天宇股份2月2日收盘报23.38元，跌10.08%，当日成交1121.42万元，已连续5日下跌。前10个交易日主力资金累计净流出1672.16万元，股价累计下跌8.61%。最近90天内共有1家机构给出评级，均为买入评级。资金流向2月2日主力资金净流出94.98万元；游资资金净流入219.65万元；散户资金净流出124.67万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300001714.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608851249","title":"2月2日天宇股份跌10.08%，湘财医药健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2608851249","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608851249?lang=zh_cn&edition=full","pubTime":"2026-02-02 16:55","pubTimestamp":1770022519,"startTime":"0","endTime":"0","summary":"证券之星消息，2月2日天宇股份跌10.08%，收盘报23.38元，换手率5.31%，成交量11.21万手，成交额2.69亿元。重仓天宇股份的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为湘财基金的湘财医药健康混合A。湘财医药健康混合A目前规模为0.16亿元，最新净值1.7571，较上一交易日上涨0.24%，近一年上涨53.4%。该公募基金现任基金经理为张泉。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200023780.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607042484","title":"天宇股份（300702）披露2025年度业绩预告，1月30日股价下跌0.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607042484","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607042484?lang=zh_cn&edition=full","pubTime":"2026-01-30 23:27","pubTimestamp":1769786833,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，天宇股份报收于26.0元，较前一交易日下跌0.38%，最新总市值为90.47亿元。该股当日开盘26.22元，最高26.5元，最低25.62元，成交额达5730.16万元，换手率为1.04%。近日，浙江天宇药业股份有限公司披露《2025年度业绩预告》。公告显示，公司预计2025年度归属于上市公司股东的净利润为12,000万元至16,000万元，同比增长114.53%至186.05%；扣除非经常性损益后的净利润为11,200万元至15,200万元，同比增长66.03%至225.32%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000048390.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606495772","title":"天宇股份（300702）披露2026年度日常关联交易预计公告，1月26日股价上涨1.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606495772","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606495772?lang=zh_cn&edition=full","pubTime":"2026-01-26 22:47","pubTimestamp":1769438823,"startTime":"0","endTime":"0","summary":"截至2026年1月26日收盘，天宇股份报收于26.87元，较前一交易日上涨1.28%，最新总市值为93.5亿元。该股当日开盘26.7元，最高27.14元，最低26.02元，成交额达1.53亿元，换手率为2.72%。近日，天宇股份披露《关于2026年度日常关联交易预计的公告》。公告显示，公司预计2026年度与上海星可及其子公司发生日常关联交易总额不超过16,000万元，其中采购原材料不超过6,000万元，销售产品不超过10,000万元；与九洲药业及其子公司销售产品不超过3,000万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600036687.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605592497","title":"天宇股份（300702）披露全资子公司药品获得批准，1月22日股价下跌1.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605592497","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605592497?lang=zh_cn&edition=full","pubTime":"2026-01-22 22:26","pubTimestamp":1769091975,"startTime":"0","endTime":"0","summary":"截至2026年1月22日收盘，天宇股份报收于26.12元，较前一交易日下跌1.36%，最新总市值为90.89亿元。该股当日开盘26.62元，最高26.66元，最低26.03元，成交额达7114.84万元，换手率为1.28%。公司近日发布公告称，其全资子公司浙江诺得药业有限公司收到国家药品监督管理局核准签发的巴氯芬片《药品注册证书》，药品批准文号为国药准字H20263133，有效期至2031年1月13日。截至目前，国内另有3家生产企业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200040870.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604131948","title":"天宇股份（300702）披露全资子公司首次通过高新技术企业认定，1月19日股价上涨1.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604131948","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604131948?lang=zh_cn&edition=full","pubTime":"2026-01-19 22:38","pubTimestamp":1768833493,"startTime":"0","endTime":"0","summary":"截至2026年1月19日收盘，天宇股份报收于25.57元，较前一交易日上涨1.03%，最新总市值为88.98亿元。该股当日开盘25.25元，最高25.58元，最低24.74元，成交额达1.02亿元，换手率为1.91%。公司近日发布公告称，其全资子公司浙江京圣药业有限公司首次通过高新技术企业认定，获得由相关部门颁发的《高新技术企业证书》，证书编号GR202533002271，发证时间为2025年12月19日，有效期三年。此次认定有助于提升公司核心竞争力，但不会对公司经营业绩产生重大影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011900035925.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601820078","title":"天宇股份(300702.SZ)：阿帕他胺原料药通过CDE审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2601820078","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601820078?lang=zh_cn&edition=full","pubTime":"2026-01-07 15:58","pubTimestamp":1767772688,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天宇股份(300702.SZ)公告，公司全资子公司浙江京圣药业有限公司(“京圣药业”)阿帕他胺原料药于近日通过国家药品监督管理局药品审评中心(“CDE”)审评。阿帕他胺是一种用于治疗前列腺癌的非甾体类抗雄激素药物，通过抑制雄激素受体信号通路发挥作用，延缓疾病进展。它主要用于非转移性去势抵抗性前列腺癌(nmCRPC)和转移性去势敏感性前列腺癌(mCSPC)，需在医生指导下联合去势治疗使用。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389792.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1223082196.USD","BK0239","BK4017","LU1223082519.USD","LU1223083913.SGD","CDE","300702"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601481323","title":"天宇股份（300702）披露变更签字注册会计师公告，1月6日股价下跌0.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601481323","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601481323?lang=zh_cn&edition=full","pubTime":"2026-01-06 22:24","pubTimestamp":1767709466,"startTime":"0","endTime":"0","summary":"截至2026年1月6日收盘，天宇股份报收于24.58元，较前一交易日下跌0.41%，最新总市值为85.53亿元。该股当日开盘24.77元，最高24.77元，最低24.28元，成交额达6176.34万元，换手率为1.19%。公司近日发布公告称，因保持独立性需要，天健会计师事务所将公司2025年度财务报表及内部控制审计的签字注册会计师由金晨希变更为周小民，变更后由周小民和李翀共同担任。周小民自2000年起在天健会计师事务所工作，2002年取得注册会计师资格，近三年未因执业行为受过处罚。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600042520.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2593416977","title":"天宇股份（300702）披露完成《公司章程》备案，12月23日股价上涨0.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593416977","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593416977?lang=zh_cn&edition=full","pubTime":"2025-12-23 22:44","pubTimestamp":1766501069,"startTime":"0","endTime":"0","summary":"截至2025年12月23日收盘，天宇股份报收于23.91元，较前一交易日上涨0.76%，最新总市值为83.2亿元。该股当日开盘23.83元，最高23.99元，最低23.61元，成交额达3942.95万元，换手率为0.79%。公司近日发布公告称，已于近期完成《公司章程》的工商备案手续。此前，公司于2025年10月29日召开董事会及监事会会议，并于2025年11月18日召开2025年第三次临时股东大会，审议通过了修订《公司章程》的议案。具体内容可参见公司同日披露的《公司章程》文件。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300041080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2593433029","title":"天宇股份（300702）披露全资子公司药品获得批准，12月22日股价下跌1.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593433029","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593433029?lang=zh_cn&edition=full","pubTime":"2025-12-22 22:35","pubTimestamp":1766414146,"startTime":"0","endTime":"0","summary":"截至2025年12月22日收盘，天宇股份报收于23.73元，较前一交易日下跌1.54%，最新总市值为82.57亿元。该股当日开盘24.08元，最高24.15元，最低23.73元，成交额达4197.12万元，换手率为0.83%。公司近日发布公告称，其全资子公司浙江诺得药业有限公司收到国家药品监督管理局核准签发的盐酸曲唑酮片《药品注册证书》，药品批准文号为国药准字H20256265，有效期至2030年12月15日。该药品适用于抑郁症治疗，注册分类为化学药品3类。公司对该品种累计研发投入约617.34万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200035038.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2593485145","title":"天宇股份最新公告：全资子公司药品盐酸曲唑酮片获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2593485145","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593485145?lang=zh_cn&edition=full","pubTime":"2025-12-22 17:45","pubTimestamp":1766396718,"startTime":"0","endTime":"0","summary":"天宇股份(300702.SZ)公告称，公司全资子公司诺得药业收到国家药监局核准签发的盐酸曲唑酮片的《药品注册证书》。该药品适用于抑郁症的治疗，对伴有或不伴有焦虑的患者均有效。截至公告日，国内生产商另有9家企业。2024年该药品在国内销售额约5.96亿元。诺得药业累计研发投入约617.34万元。该药品获得批件后可在境内生产、销售，有望增加公司制剂业务收入，提升市场竞争力，对公司经营业绩产生积极影响。但药品未来生产、销售情况可能受市场环境变化等因素影响，盈利水平具有不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200022051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1776764796486,"stockEarnings":[{"period":"1week","weight":-0.0397},{"period":"1month","weight":0.0291},{"period":"3month","weight":-0.1348},{"period":"6month","weight":-0.1113},{"period":"1year","weight":0.1332},{"period":"ytd","weight":-0.0559}],"compareEarnings":[{"period":"1week","weight":0.0235},{"period":"1month","weight":0.0316},{"period":"3month","weight":-0.0077},{"period":"6month","weight":0.043},{"period":"1year","weight":0.2458},{"period":"ytd","weight":0.0285}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江天宇药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"15238人(较上一季度减少8.06%)","perCapita":"13857股","listingDate":"2017-09-19","address":"浙江省台州市黄岩区黄岩江口化工开发区","registeredCapital":"34797万元","survey":" 浙江天宇药业股份有限公司的主营业务是中间体、原料药以及制剂业务的研发、生产与销售。公司的主要产品是降血压类原料药及中间体、降血糖类原料药及中间体、抗凝血类原料药及中间体、制剂类、抗哮喘类原料药及中间体、降血脂类原料药及中间体。","listedPrice":22.41},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"天宇股份(300702)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供天宇股份(300702)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"天宇股份,300702,天宇股份股票,天宇股份股票老虎,天宇股份股票老虎国际,天宇股份行情,天宇股份股票行情,天宇股份股价,天宇股份股市,天宇股份股票价格,天宇股份股票交易,天宇股份股票购买,天宇股份股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"天宇股份(300702)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供天宇股份(300702)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}